Brokerages Set Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Price Target at $18.30
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the eleven research firms that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have issued a buy rating and two […]
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the eleven research firms that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have issued a buy rating and two […]
